Mechanism of Action
Mimics ghrelin — binds ghrelin receptors (GHSR) in the pituitary and hypothalamus, stimulating pulsatile growth hormone release. Downstream IGF-1 elevation is consistent. Does not directly suppress testosterone or bind androgen receptors. Increases appetite significantly through ghrelin pathway activation.
Ester Profile
Oral non-steroidal compound. No ester used. Long half-life of approximately 24 hours allows once-daily oral dosing.
How It's Used in Fitness
MK-677 fills a specific niche as an orally active compound that increases growth hormone and IGF-1 without direct androgen receptor activity. It is used during mass phases for the combined effects of increased appetite, improved sleep quality, accelerated recovery, and the anabolic environment created by elevated GH and IGF-1. Some athletes use it specifically to improve sleep and recovery without any particular concern for muscle gain as a primary goal. It also appears in bridging protocols between cycles where someone wants to maintain an anabolic environment without suppressing their hormonal axis, since MK-677 does not suppress testosterone.
Stacking Context
MK-677 is frequently combined with other SARMs, particularly RAD-140 or LGD-4033, in stacks that aim to combine androgen receptor-mediated muscle growth with GH axis stimulation. It is also used alongside traditional anabolic stacks as a recovery and sleep enhancement addition, though this use pattern creates a more complex risk profile because the GH elevation compounds the anabolic and metabolic effects of the androgens already present. Some users run it as a solo compound specifically for the sleep and recovery benefits without any additional anabolic agent.
Medical Use
- Investigated for growth hormone deficiency
- Hip fracture recovery trials
- Alzheimer's disease trials (IGF-1 related)
- No approved therapeutic use
Side Effects
- Insulin resistance — significant and well-documented
- Water retention — GH-mediated, can be substantial
- Increased appetite — through ghrelin agonism
- Lethargy and fatigue — especially early in use
- Potential IGF-1 driven proliferation concerns with chronic use
- Joint pain — water retention in joint spaces
- Elevated fasting glucose in predisposed individuals
What Actually Goes Wrong
The insulin resistance that MK-677 causes is the most practically significant risk and it is one that users frequently ignore until it manifests as noticeable changes in fasting glucose or body composition response. Chronic elevation of GH and IGF-1 has proliferative potential, meaning it may accelerate the growth of existing pre-cancerous cells. This risk is not proven in the human data available for MK-677 specifically but it is a mechanistic concern that is not unreasonable given what is known about IGF-1 biology. The water retention it produces is often dramatic and can mask fat loss progress, creating a misleading picture of body composition changes during use.
Detection Window
WADA bans all GH secretagogues. Specific detection methodology for MK-677 in anti-doping context evolving.
MK-677 is often presented as consequence-free because it does not suppress testosterone and is taken orally. The insulin resistance issue alone should give anyone pause, particularly if there is any personal or family history of metabolic dysfunction. The water retention is cosmetically counterproductive for anyone whose goal is a lean appearance. If the primary goal is better sleep and recovery, there are lower-risk paths to those outcomes that do not involve chronically elevated IGF-1.